Company intelligence / Profile preview

Holtzbrinck Ventures

Munich, Bavaria, Germany

Ownership: Private
Employees: ~22
Development stage: Other

Overview

HV Capital, historically associated with the name Holtzbrinck Ventures or HV Holtzbrinck Ventures, is a European venture capital investor rather than a drug-development company. The firm backs early-stage and growth-stage technology businesses across sectors such as digital health, fintech, climate tech, education, B2B SaaS, deep tech, and AI. Available public sources indicate that the current active brand is HV Capital, while a related but distinct entity, Dieter von Holtzbrinck Ventures (DvH Ventures), operates separately under the DvH Ventures name. For biotech-analyst purposes, this entity is best classified as an investor with some healthcare exposure, not as a therapeutics developer, platform biotech, pharma company, CRO, or CDMO.

Industry: Investors

Beyond the preview

Go deeper on Holtzbrinck Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Holtzbrinck Ventures.

Explore the full profile